homepage-top-section

The therapy is indicated for children who are either new to treatment or have prior experience with antiretroviral therapies but have not been treated with integrase strand transfer

Utilising its analytical platforms such as next-generation sequencing (NGS), Charles River will assist with chemistry, manufacturing, and controls (CMC) activities related to the vaccine’s development. The agreement aims

The designation applies specifically to patients whose tumours contain a phosphatidylinositol 3-kinase / protein kinase B / mechanistic target of rapamycin (PI3K/AKT/mTOR) pathway alteration. It also applies to

This initiative builds on an established partnership between the two companies, under which BMS already utilises Schrödinger’s computational platform for drug discovery projects. The new arrangement will extend

The deal will take the Nasdaq-listed Lantheus private. Under the agreement, Curium US will purchase all outstanding shares of Lantheus for $102.50 per share upon closing. Lantheus’ shareholders

The investment will support the expansion of Resilience’s advanced manufacturing operations in the Cincinnati region and create at least 400 new jobs. With this initiative, the total number

The deal grants CORE Biomedicine rights to develop and commercialise a portfolio of cancer therapies originally discovered by Eisai and its affiliates. The licensed assets focus on targeting

Approved by both companies’ boards of directors, the transaction is expected to close in the third quarter of 2026, contingent upon standard closing conditions. The main asset involved

This combination aims to provide an additional non-opioid pain relief option without the need for prescriptions. The approval introduces a new choice for individuals seeking relief from persistent